abstract |
The invention relates to fused cyclic compounds of the formula wherein the substituents are as defined in the specification, to methods for their use in the treatment of conditions associated with a nuclear hormone receptor such as cancer and immune disorders and to pharmaceutical compositions comprising such compounds . |